Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Research and Development

Report: $35.6 Billion Invested Globally in University Spinouts Between 2013-2016

Washington, DC, June 22, 2017 — Over the past four years, 1,668 deals involving university spinout companies from across the globe attracted approximately $35.6 billion from 2013 to 2016, according to a new report from Global University Venturing.

The report, however, highlights that global deals peaked in 2014 with 529 deals and total investments dollars peaked in 2015 with nearly $14 billion invested.

As the authors highlighted, these global numbers were unsustainable and 2016 saw significant declines in both deals and dollars. In 2016, the total deals reported were 407 (21.6 percent decrease from 2015) and dollars invested was $6.4 billion (a 54.3 percent decrease from 2015). Continue reading

Medical Research, Science Funding Spared Under Budget Deal — But More Battles Ahead

Washington, DC, May 2, 2017 —Joel Achenbach, Ben Guarino, Sarah Kaplan and Darryl Fears report in The Washington Post that the lights will stay on in the federal government, and also in the countless laboratories and universities that depend on federal funding for scientific and medical research.

That’s one upshot of the bipartisan budget deal congressional negotiators reached late Sunday.

The bill, clocking in at more than 1,600 pages, is likely to pass both houses of Congress and be signed into law by President Trump this week.  It covers funding through September. Continue reading

Rebuffing Trump’s Call for Cuts, Congress Boosts NIH Funding by $2 Billion

Washington, DC, May 1, 2017 — Lev Facher reports in STAT that the National Institutes of Health will get a $2 billion funding boost over the next five months, under a bipartisan spending deal reached late Sunday night in Congress.

The agreement marks a sharp rejection of President Trump’s proposal to cut $1.2 billion from the medical research agency in the current fiscal year.

The deal does not address funding for 2018, when Trump has called for a slashing the NIH’s budget by about a fifth, or $5.8 billion. Continue reading

Boston Consulting Group Report Shows Private-Public Research Consortia Fundamental to U.S. Competitiveness

Westerville, OH, May 1, 2017 ― The State Science & Technology Institute (SSTI) reports that, while the United States remains the global leader in overall research and development (R&D) spending, China has surpassed the U.S. in later-stage technological investments, according to a new report by the Boston Consulting Group (BCG).

At its current rate of growth, the authors find that China’s investment in later-stage R&D could double that of the U.S. by 2018.

Their analysis suggests that there is significant potential for the U.S to get more out of its R&D by strengthening the relationships between industry and research institutions. Continue reading

Deloitte Report: Driving Medical Innovation Through Biopharmaceutical Collaboration.

Washington, DC, April 18, 2017 — Emma Van Hook, a director of Policy & Research at the Pharmaceutical Research and Manufacturers of America (PhRMA), reports on The Catalyst that a new report from Deloitte examines the changing landscape of biopharmaceutical research, as stakeholders across the research and development (R&D) ecosystem are increasingly coming together to tackle sciences’ most vexing health challenges.

The new research illustrates there has been a significant shift in recent years from traditional, asset-based or transactional agreements to more open, collaborative approaches for conducting biopharmaceutical research.

Deloitte compiled and analyzed a database of thousands of partnerships initiated between 1995 and 2014. Continue reading

National Science Foundation Study: U.S. Companies Performed 18 Percent of R&D Outside the U.S. in 2013;

Washington, DC, April 18, 2017 — U.S. companies spent $73 billion on research and development (R&D) performed outside the United States in 2013, according to a new report by the National Science Foundation’s National Center for Science and Engineering Statistics.

The total represented 18 percent of U.S. companies’ total R&D performance.  These same companies spent $323 billion on R&D performed within the United States in 2013.

Almost 50 percent of the foreign R&D performance by U.S. companies was in Europe, largely in the United Kingdom and Germany. Continue reading